Company Registration No. 15299935 (England and Wales)
Future Medicine Limited
Unaudited accounts
for the year ended 31 December 2025
Future Medicine Limited
Unaudited accounts
Contents
Future Medicine Limited
Company Information
for the year ended 31 December 2025
Directors
James Jean-Pierre Drake
Danny Alexander Al-Khafaji
Company Number
15299935 (England and Wales)
Registered Office
Future Medicine Ltd
1 Albert Place
London
London
N3 1QB
England
Future Medicine Limited
Statement of financial position
as at 31 December 2025
Tangible assets
1,545
2,318
Cash at bank and in hand
5,418
49,257
Creditors: amounts falling due within one year
(801,988)
(411,755)
Net current liabilities
(607,703)
(300,494)
Net liabilities
(606,158)
(298,176)
Called up share capital
100
100
Profit and loss account
(606,258)
(298,276)
Shareholders' funds
(606,158)
(298,176)
For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 8 June 2026 and were signed on its behalf by
Danny Alexander Al-Khafaji
Director
Company Registration No. 15299935
Future Medicine Limited
Notes to the Accounts
for the year ended 31 December 2025
Future Medicine Limited is a private company, limited by shares, registered in England and Wales, registration number 15299935. The registered office is Future Medicine Ltd, 1 Albert Place, London, London, N3 1QB, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
25% Straight Line
Fixtures & fittings
25% Straight Line
The accounts have been prepared on the going concern basis which assumes the continued support of Mr James Drake, who is a director of the company.
4
Tangible fixed assets
Plant & machinery
Fixtures & fittings
Total
Cost or valuation
At cost
At cost
At 1 January 2025
1,608
1,483
3,091
At 31 December 2025
1,608
1,483
3,091
At 1 January 2025
402
371
773
Charge for the year
402
371
773
At 31 December 2025
804
742
1,546
At 31 December 2025
804
741
1,545
At 31 December 2024
1,206
1,112
2,318
Future Medicine Limited
Notes to the Accounts
for the year ended 31 December 2025
Amounts falling due within one year
Amounts due from group undertakings etc.
164,245
44,482
Other debtors
11,250
11,250
6
Creditors: amounts falling due within one year
2025
2024
Trade creditors
20,731
25,470
Taxes and social security
5,123
3,948
Loans from directors
773,134
379,337
7
Transactions with related parties
Creditors as at 31 December 2025 include an amount of £773,134 (2024: £379,337) payable to Mr James Drake who is a director of the company. Other debtors as at 31 December 2025 include amounts of £56,607 (2024: 35,205) from Of Lost Time Limited, £98,361 (2024: nil) from Art and Science UK Limited and £9,277 (2024: £9,277) from The Drake Foundation, which is not-for profit company, where Mr James Drake is a director of all three companies.
8
Average number of employees
During the year the average number of employees was 4 (2024: 3).